Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of EQ143 in Severe Hepatic Impairment
NCT05199610Phase 1Completed
- Sponsor
- EQRx
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by EQRx. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last quantifiable concentration and 3 more. Started Mar 2022; status: completed.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05199610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199610.